Verona Pharma Plc Stock London S.E.
Equities
GB00B06GSH43
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
05-09 | Verona Pharma Signs Financing Agreements for Up to $650 Million | MT |
05-09 | Verona Pharma Shares Decline After Q1 Loss Widens | MT |
Sales 2024 * | 5.3M 6.63M 9.07M | Sales 2025 * | 75.71M 94.8M 130M | Capitalization | 961M 1.2B 1.65B |
---|---|---|---|---|---|
Net income 2024 * | -104M -130M -178M | Net income 2025 * | -65M -81.39M -111M | EV / Sales 2024 * | 147 x |
Net cash position 2024 * | 184M 230M 315M | Net cash position 2025 * | 146M 183M 251M | EV / Sales 2025 * | 10.8 x |
P/E ratio 2024 * |
-15.7
x | P/E ratio 2025 * |
-37.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma Plc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |